ライブラリ登録: Guest
Critical Reviews™ in Eukaryotic Gene Expression

年間 6 号発行

ISSN 印刷: 1045-4403

ISSN オンライン: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Emerging Trends in Non-Interferon-Based Genotype-Specific Antiviral Agents: Pharmaceutical Perspectives

巻 27, 発行 4, 2017, pp. 305-319
DOI: 10.1615/CritRevEukaryotGeneExpr.2017019956
Get accessGet access

要約

Hepatitis C virus (HCV) presents a serious global health threat. Initially, the health-care community mainly focused on interferon (IFN)-based therapeutic options to eradicate HCV, but with the passage of time, these applications became unsuitable due to some serious side effects related to the use of IFN. In recent years, research conducted on different phases of HCV's life cycle has opened a new gateway for the use of a direct-acting new generation of anti-HCV agents. Their safer and ultrarapid response has made possible the introduction of triple therapy and use of IFN-free therapeutic treatment strategies. However, the high cost of these successful therapies has raised serious concerns, particularly in low-income countries, and this has forced pharmaceutical scientists to explore more cost-effective IFN-free alternatives for the treatment of HCV. In this article, we have briefly summarized the latest data regarding the research and development of non-IFN-based antiviral agents. The studies mentioned in this article highlight the significance of non-IFN-based direct-acting antiviral (DAA) agents. Economical alternative anti-HCV agents are expected to become available in the near future for better and more cost-effective treatments of HCV.

877 記事の閲覧数 16 記事のダウンロード 記事の統計
877 記事の閲覧数 16 記事のダウンロード Google
Scholar
引用数

類似内容の記事:

What's New in Allergen Immunotherapy Patents? A Review Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.38, 2021, issue 6
Mairim Russo Serafini, Tiago Bittencourt de Oliveira, Anamaria Mendonça Santos, Carina Carvalho dos Santos, Izabel Almeida Alves
Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 3
Rohit Bhosale, Bannimath Gurupadayya, Devegowda Vishakante Gowda, Koganti Venkata Sairam, Riyaz Ali Mahafez Ali Osmani, Rudra Vaghela, Hosahalli Veerabhadrappa Gangadharappa, Parthasarathi Keshavarao Kulkarni
Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 1
Preshita Desai, Jeffrey Wang, Sunil Prabhu, David Ann
Antiretroviral Agents: Looking for the Best Possible Chemotherapeutic Options to Conquer HIV Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 4
Tahir Farooq, Muhammad Ibrahim, Muhammad Imran Qadir, Muhammad Sajid Hamid Akash, Kanwal Rehman, Arruje Hameed
Treatment of Hepatitis C Virus Infection With Interferon and Small Molecule Direct Antivirals: Viral Kinetics and Modeling Critical Reviews™ in Immunology, Vol.30, 2010, issue 2
Alan S. Perelson, Libin Rong
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain